Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
Stocks in this Quantisnow insightHealth Care
Historical context for NXL
Across the 18 sessions after earlier NXL headlines, the stock closed higher 8 times and lower 10 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NXL | SPY |
|---|---|---|---|
| May 19, 2026 | Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial | -1.1% | -0.7% |
| Apr 28, 2026 | Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia | -8.6% | -0.5% |
| Apr 15, 2026 | Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China | +18.5% | +0.8% |
| Apr 14, 2026 | Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21 | -0.3% | +1.2% |
| Apr 9, 2026 | Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents | +8.6% | +0.6% |
| Feb 24, 2026 | Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market | +15.0% | +0.7% |
Keep researching NXL
Quantisnow market dataNASDAQ
NXL
Nexalin Technology Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Listed since
- 2022
Get push alerts for NXL
Full NXL profile on Quantisnow Follow NXL and get a push notification the moment its next story breaks.